M&A Deal Summary

Therapix Biosciences Acquires Destiny Biosciences Global

On July 23, 2019, Therapix Biosciences acquired life science company Destiny Biosciences Global for 48M USD

Acquisition Highlights
  • This is Therapix Biosciences’ 2nd transaction in the Life Science sector.
  • This is Therapix Biosciences’ largest (disclosed) transaction.
  • This is Therapix Biosciences’ 1st transaction in Canada.
  • This is Therapix Biosciences’ 1st transaction in Alberta.

M&A Deal Summary
Date 2019-07-23
Target Destiny Biosciences Global
Sector Life Science
Buyer(s) Therapix Biosciences
Deal Type Merger
Deal Value 48M USD

Target

Destiny Biosciences Global

Nisku, Alberta, Canada
Destiny Biosciences Global Corp. is a science-based cannabis genetics and tissue culture research and development company. Destiny Biosciences Global Corp. was founded in 2018 and is based in Nisku, Alberta.

Search 199,713 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Therapix Biosciences

Ness Ziona, Israel
Category Company
Founded 2004
Sector Life Science
DESCRIPTION

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists. Its focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on repurposing an FDA-approved cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Merger) 1 of 1
State (Alberta) 1 of 1
Country (Canada) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-10-21 Dekel Pharmaceuticals

Ramat Gan, Israel

Dekel Pharmaceuticals Ltd. is a privately-held company engaged in the research and development of drug therapies based on synthetic cannabinoid substances.

Buy -
Mergr

Product

Company

Legal